Logo

Panagene to Supply Dako with PNA Probes

Feb 22, 2013 | staff reporter

NEW YORK (GenomeWeb News) – South Korean firm Panagene today said that it has signed an agreement to provide Dako with Peptide Nucleic Acid probes for use in diagnostic or research products.

PNA is an artificially synthesized DNA analogue that Panagene said has higher binding affinity, specificity, and sensitivity to a target, as well as high biological/chemical stability. Terms of the agreement were not disclosed.

Dako currently offers a telomere PNA kit for flow cytometry, which measures telomeric sequences in vertebrate interphase hematopoietic cells, a PNA ISH detection kit for performing in situ hybridization, and an Epstein-Barr Virus PNA Probe/Fluorescein product for detecting the two nuclear RNA transcripts EBER1 and EBER2 encoded by Epstein-Barr virus.

Dako is part of Agilent Technologies, following a $2.2 billion acquisition last year.

Filed under

PCR
Diagnostics
Business News
licensing agreement
Agilent
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.